The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Klisyri tirbanibulin Additional monitoring | Almirall, S.A. | Keratosis, Actinic | 🇪🇺 EU 2021-07-16 | Order → |
| Ryeqo relugolix;estradiol;norethisterone acetate | Gedeon Richter Plc. | Leiomyoma | 🇪🇺 EU 2021-07-16 | Order → |
| Skysona elivaldogene autotemcel PRIMEATMPAdditional monitoring | bluebird bio (Netherlands) B.V. | Adrenoleukodystrophy | 🇪🇺 EU 2021-07-16 | Order → |
| Verquvo vericiguat | Bayer AG | Heart Failure | 🇪🇺 EU 2021-07-16 | Order → |
| Abiraterone Krka abiraterone acetate Generic | KRKA tovarna zdravil d.d. Novo mesto | Prostatic Neoplasms | 🇪🇺 EU 2021-06-24 | Order → |
| Enspryng satralizumab Orphan | Roche Registration GmbH | Neuromyelitis Optica | 🇪🇺 EU 2021-06-24 | Order → |
| Jayempi azathioprine | Lipomed GmbH | Graft Rejection | 🇪🇺 EU 2021-06-21 | Order → |
| Adtralza tralokinumab | LEO Pharma A/S | Dermatitis, Atopic | 🇪🇺 EU 2021-06-17 | Order → |
| Celsunax ioflupane (123I) Generic | Pinax Pharma GmbH | Radionuclide Imaging; Dementia; Movement Disorders | 🇪🇺 EU 2021-06-17 | Order → |
| Evkeeza evinacumab Exceptional circumstancesAdditional monitoring | Ultragenyx Germany GmbH | Hypercholesterolemia | 🇪🇺 EU 2021-06-17 | Order → |
| Koselugo selumetinib OrphanConditionalAdditional monitoring | AstraZeneca AB | Neurofibromatosis 1 | 🇪🇺 EU 2021-06-17 | Order → |
| Onureg azacitidine | Bristol-Myers Squibb Pharma EEIG | Leukemia, Myeloid, Acute | 🇪🇺 EU 2021-06-17 | Order → |
| Efmody hydrocortisone | Immedica Pharma AB | Adrenal Hyperplasia, Congenital | 🇪🇺 EU 2021-05-27 | Order → |
| Copiktra duvelisib Additional monitoring | Secura Bio Limited | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | 🇪🇺 EU 2021-05-19 | Order → |
| Drovelis estetrol;drospirenone Additional monitoring | Gedeon Richter Plc. | Contraceptives, Oral | 🇪🇺 EU 2021-05-19 | Order → |
| Lydisilka estetrol;drospirenone Additional monitoring | Estetra SPRL | Contraceptives, Oral | 🇪🇺 EU 2021-05-19 | Order → |
| Ponvory ponesimod | Laboratoires Juvisé Pharmaceuticals | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2021-05-19 | Order → |
| Orladeyo berotralstat | Neopharmed Gentili Ireland Limited | Angioedemas, Hereditary | 🇪🇺 EU 2021-04-30 | Order → |
| Sibnayal potassium citrate;potassium hydrogen carbonate | Advicenne S.A. | Acidosis, Renal Tubular | 🇪🇺 EU 2021-04-30 | Order → |
| Abiraterone Accord abiraterone Generic | Accord Healthcare S.L.U. | Prostatic Neoplasms | 🇪🇺 EU 2021-04-26 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.